Ipamorelin: A Selective Pentapeptide Growth Hormone Secretagogue

Research summary. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed in the 1990s. It distinguished itself from earlier GHRPs (GHRP-2, GHRP-6, hexarelin) through its highly selective engagement of the growth hormone secretagogue receptor (GHS-R1a) without significant stimulation of cortisol, prolactin, ACTH, or other off-target hormones — a profile that has supported its widespread use as a research tool when "clean" GHS-R1a engagement is desired.

Molecular profile

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Molecular formula: C₃₈H₄₉N₉O₅
• Molecular weight: ~711.9 g/mol
• Class: Pentapeptide GHS-R1a agonist
• Origin: Developed by Novo Nordisk in the 1990s as part of a programme aimed at GHRPs with cleaner GH-axis selectivity

The structure includes the unusual amino-acid α-aminoisobutyric acid (Aib) at position 1 and two D-amino-acid aromatic residues (D-2-naphthylalanine and D-phenylalanine), which together provide protease resistance while preserving GHS-R1a binding.

Mechanism of action

Ipamorelin engages the GHS-R1a (ghrelin receptor) with high selectivity, producing:

• GH release from anterior pituitary somatotrophs through Gαq/PLC/IP3 calcium signalling
• Synergy with GHRH analogues at GHRH receptor — a separate receptor system — producing greater than additive GH secretion when combined
• Minimal effect on other anterior pituitary hormones including cortisol, ACTH, and prolactin, distinguishing ipamorelin from GHRP-6 and GHRP-2 which more readily affect these axes
• Minimal CD36 engagement relative to GHRP-6 and hexarelin, contributing to the cleaner pharmacological profile

The selectivity profile is the principal reason ipamorelin became the preferred GHRP-class research tool when the goal is to study GHS-R1a-mediated GH release with minimal off-target signalling.

Preclinical research highlights

Selective GH release. Foundational pharmacological characterisation by Raun and colleagues at Novo Nordisk reported that ipamorelin produces GH release of comparable magnitude to GHRP-6 in pituitary preparations but without the cortisol or prolactin elevations characteristic of the earlier GHRPs [1].

Skeletal effects. Rat studies have reported increases in cortical bone mineral content, expanded femur and lumbar vertebra volumes, and improved bone-density markers following sustained ipamorelin administration. Effects on longitudinal bone growth and body weight have been described in juvenile-rat studies, attributed to GH-IGF-1 axis stimulation downstream of the receptor engagement.

Postoperative ileus research. A clinical-development line of work explored ipamorelin (under the development name TZP-101 / ulimorelin in the related ghrelin-mimetic class) for postoperative ileus, with reported reductions in time to first tolerated meal in some studies. The development pathway did not produce broad regulatory approval.

Combination with GHRH analogues. Ipamorelin is widely used in combination with GHRH-class peptides (CJC-1295, sermorelin, tesamorelin) as a research strategy to engage both branches of the GH-axis simultaneously. The two receptor systems converge on GH release with clear synergy, producing larger GH peaks than either component alone.

Tolerability. Across reported studies, the absence of cortisol/prolactin responses and the relatively short duration of action have been associated with a tolerability profile that has supported the molecule's widespread research use.

Position in the GHRP family

Ipamorelin's relationship to its sibling peptides:

• GHRP-6: Older, less selective at GHS-R1a, prominent CD36 engagement, more pronounced appetite stimulation
• GHRP-2: More potent at GH release than ipamorelin but with cortisol/prolactin effects
• Hexarelin: Highest GH-releasing potency but with prominent CD36 engagement and broader effects
• Ipamorelin: Most selective for GHS-R1a-driven GH release, minimal off-target effects
• MK-677 (ibutamoren): Non-peptide small molecule alternative with oral bioavailability

When research aims to isolate GHS-R1a-driven GH release from other GHRP effects, ipamorelin is typically the preferred peptide.

Why selectivity matters

The earlier-generation GHRPs (GHRP-6, GHRP-2, hexarelin) produce a complex pharmacological profile that includes appetite stimulation (via hypothalamic ghrelin signalling), cortisol elevation (via ACTH co-stimulation), prolactin elevation, and CD36 engagement on multiple cell types. Each of these activities can be experimentally interesting in its own right, but they confound studies aiming to isolate the GH-IGF-1 axis. Ipamorelin's cleaner profile reflects the natural maturation of the GHRP class toward more receptor-selective tool compounds — a pattern subsequently extended further by non-peptide small-molecule agonists like MK-677.

Current research status

Ipamorelin remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. It is listed by the World Anti-Doping Agency as a prohibited substance under category S2 (peptide hormones, growth factors, related substances and mimetics). Active research applications include:

• GH-axis biology in basic and clinical research contexts
• Skeletal muscle and bone metabolism studies
• Combination GHRP/GHRH research
• Reference compound for development of newer GHS-R1a agonists

Key takeaways for researchers

• Ipamorelin is a pentapeptide GHS-R1a agonist with high selectivity for GH release, minimal cortisol/prolactin effects, and minimal CD36 engagement.
• It is the preferred GHRP-class tool peptide when "clean" GHS-R1a engagement is desired.
• It is widely combined with GHRH analogues for synergistic engagement of both GH-axis pathways.
• It is on the WADA Prohibited List and is not an approved therapeutic.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561.

---

This article is provided for educational and research purposes only. Ipamorelin is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. Ipamorelin is listed by the World Anti-Doping Agency as a prohibited substance. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.